Accretion Pharmaceuticals Reports Strong H1 FY27 Performance with 72.6% PAT Surge
Accretion Pharmaceuticals Ltd · Outcome · 02 Nov 2026, 5:38 pm
Accretion Pharmaceuticals Reports Strong H1 FY27 Performance with 72.6% PAT Surge Accretion Pharmaceuticals reported revenue from operations of ₹5,504.10 lakhs for the half-year ended 30th Sep'26, up 25.8% YoY from ₹4,373.62 lakhs. Profit Before Tax climbed 69.2% YoY to ₹1,084.49 lakhs compared to ₹641.07 lakhs in H1 FY26. Net profit surged 72.6% YoY to ₹820.14 lakhs from ₹475.22 lakhs, expanding diluted EPS to ₹7.38 from ₹4.61. Operating cash outflow stood at ₹312.14 lakhs due to working capital additions. Net worth reached ₹6,291.00 lakhs with total borrowings at ₹1,673.70 lakhs.
Original exchange filing (PDF)
More announcements from Accretion Pharmaceuticals Ltd
- Accretion Pharmaceuticals Limited has informed the Exchange about General Updates · 16 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Investor Presentation · 03 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled "Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%". · 31 Oct 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026. · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 31 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report. · 12 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company. · 11 Oct 2026
